Are  ||| S:0 E:4 ||| VBP
low  ||| S:4 E:8 ||| JJ
levels  ||| S:8 E:15 ||| NNS
of  ||| S:15 E:18 ||| IN
25-hydroxyvitamin  ||| S:18 E:36 ||| NNP
D  ||| S:36 E:38 ||| NNP
a  ||| S:38 E:40 ||| DT
risk  ||| S:40 E:45 ||| NN
factor  ||| S:45 E:52 ||| NN
for  ||| S:52 E:56 ||| IN
cardiovascular  ||| S:56 E:71 ||| JJ
diseases  ||| S:71 E:80 ||| NNS
or  ||| S:80 E:83 ||| CC
malignancies  ||| S:83 E:96 ||| NN
in  ||| S:96 E:99 ||| IN
renal  ||| S:99 E:105 ||| JJ
transplantation ||| S:105 E:120 ||| NN
?  ||| S:120 E:122 ||| .
Observational  ||| S:122 E:136 ||| JJ
studies  ||| S:136 E:144 ||| NNS
in  ||| S:144 E:147 ||| IN
healthy  ||| S:147 E:155 ||| JJ
people  ||| S:155 E:162 ||| NNS
suggest  ||| S:162 E:170 ||| VBP
an  ||| S:170 E:173 ||| DT
inverse  ||| S:173 E:181 ||| JJ
relationship  ||| S:181 E:194 ||| NN
between  ||| S:194 E:202 ||| IN
25-hydroxy-vitamin  ||| S:202 E:221 ||| NNP
D  ||| S:221 E:223 ||| NNP
( ||| S:223 E:224 ||| -LRB-
25 ||| S:224 E:226 ||| CD
( ||| S:226 E:227 ||| -LRB-
OH ||| S:227 E:229 ||| NNP
) ||| S:229 E:230 ||| -RRB-
D  ||| S:230 E:232 ||| NNP
levels ||| S:232 E:238 ||| NNS
)  ||| S:238 E:240 ||| -RRB-
and  ||| S:240 E:244 ||| CC
cardiovascular  ||| S:244 E:259 ||| JJ
diseases  ||| S:259 E:268 ||| NNS
and  ||| S:268 E:272 ||| CC
malignancies ||| S:272 E:284 ||| NN
.  ||| S:284 E:286 ||| .
We  ||| S:286 E:289 ||| PRP
performed  ||| S:289 E:299 ||| VBD
an  ||| S:299 E:302 ||| DT
observational  ||| S:302 E:316 ||| JJ
prospective  ||| S:316 E:328 ||| JJ
study  ||| S:328 E:334 ||| NN
in  ||| S:334 E:337 ||| IN
renal  ||| S:337 E:343 ||| JJ
transplant  ||| S:343 E:354 ||| NN
recipients  ||| S:354 E:365 ||| NNS
to  ||| S:365 E:368 ||| TO
investigate  ||| S:368 E:380 ||| VB
the  ||| S:380 E:384 ||| DT
effects  ||| S:384 E:392 ||| NNS
of  ||| S:392 E:395 ||| IN
vitamin  ||| S:395 E:403 ||| JJ
D  ||| S:403 E:405 ||| NNP
deficiency  ||| S:405 E:416 ||| NN
on  ||| S:416 E:419 ||| IN
cardiovascular  ||| S:419 E:434 ||| JJ
and  ||| S:434 E:438 ||| CC
malignancy  ||| S:438 E:449 ||| JJ
risks ||| S:449 E:454 ||| NNS
.  ||| S:454 E:456 ||| .
From  ||| S:456 E:461 ||| IN
389  ||| S:461 E:465 ||| CD
renal  ||| S:465 E:471 ||| JJ
transplant  ||| S:471 E:482 ||| NN
recipients ||| S:482 E:492 ||| NNS
,  ||| S:492 E:494 ||| ,
331  ||| S:494 E:498 ||| CD
with  ||| S:498 E:503 ||| IN
a  ||| S:503 E:505 ||| DT
functioning  ||| S:505 E:517 ||| JJ
graft  ||| S:517 E:523 ||| NN
at  ||| S:523 E:526 ||| IN
12  ||| S:526 E:529 ||| CD
months  ||| S:529 E:536 ||| NNS
were  ||| S:536 E:541 ||| VBD
included  ||| S:541 E:550 ||| VBN
in  ||| S:550 E:553 ||| IN
the  ||| S:553 E:557 ||| DT
study ||| S:557 E:562 ||| NN
.  ||| S:562 E:564 ||| .
Mineral  ||| S:564 E:572 ||| JJ
metabolism  ||| S:572 E:583 ||| NN
parameters  ||| S:583 E:594 ||| NNS
were  ||| S:594 E:599 ||| VBD
measured  ||| S:599 E:608 ||| VBN
at  ||| S:608 E:611 ||| IN
1 ||| S:611 E:612 ||| CD
,  ||| S:612 E:614 ||| ,
3 ||| S:614 E:615 ||| CD
,  ||| S:615 E:617 ||| ,
4  ||| S:617 E:619 ||| CD
and  ||| S:619 E:623 ||| CC
12  ||| S:623 E:626 ||| CD
months ||| S:626 E:632 ||| NNS
.  ||| S:632 E:634 ||| .
Information  ||| S:634 E:646 ||| NN
regarding  ||| S:646 E:656 ||| VBG
the  ||| S:656 E:660 ||| DT
cardiovascular  ||| S:660 E:675 ||| JJ
events  ||| S:675 E:682 ||| NNS
and  ||| S:682 E:686 ||| CC
malignancies  ||| S:686 E:699 ||| NNS
were  ||| S:699 E:704 ||| VBD
collected  ||| S:704 E:714 ||| VBN
from  ||| S:714 E:719 ||| IN
an  ||| S:719 E:722 ||| DT
electronic  ||| S:722 E:733 ||| JJ
database ||| S:733 E:741 ||| NN
.  ||| S:741 E:743 ||| .
According  ||| S:743 E:753 ||| VBG
to  ||| S:753 E:756 ||| TO
the  ||| S:756 E:760 ||| DT
1-year  ||| S:760 E:767 ||| JJ
mean  ||| S:767 E:772 ||| NN
of  ||| S:772 E:775 ||| IN
25 ||| S:775 E:777 ||| CD
( ||| S:777 E:778 ||| -LRB-
OH ||| S:778 E:780 ||| NNP
) ||| S:780 E:781 ||| -RRB-
D  ||| S:781 E:783 ||| NNP
levels ||| S:783 E:789 ||| NNS
,  ||| S:789 E:791 ||| ,
75  ||| S:791 E:794 ||| CD
recipients  ||| S:794 E:805 ||| NNS
( ||| S:805 E:806 ||| -LRB-
22.7 ||| S:806 E:810 ||| NNP
% ||| S:810 E:811 ||| NN
)  ||| S:811 E:813 ||| -RRB-
had  ||| S:813 E:817 ||| VBD
a  ||| S:817 E:819 ||| DT
normal  ||| S:819 E:826 ||| JJ
vitamin  ||| S:826 E:834 ||| JJ
D  ||| S:834 E:836 ||| NNP
status ||| S:836 E:842 ||| NN
,  ||| S:842 E:844 ||| ,
161  ||| S:844 E:848 ||| CD
( ||| S:848 E:849 ||| -LRB-
48.6 ||| S:849 E:853 ||| CD
% ||| S:853 E:854 ||| NN
)  ||| S:854 E:856 ||| -RRB-
had  ||| S:856 E:860 ||| VBD
insufficiency  ||| S:860 E:874 ||| JJ
and  ||| S:874 E:878 ||| CC
95  ||| S:878 E:881 ||| CD
( ||| S:881 E:882 ||| -LRB-
28.7 ||| S:882 E:886 ||| CD
% ||| S:886 E:887 ||| NN
)  ||| S:887 E:889 ||| -RRB-
had  ||| S:889 E:893 ||| VBD
deficiency  ||| S:893 E:904 ||| NN
in  ||| S:904 E:907 ||| IN
vitamin  ||| S:907 E:915 ||| JJ
D  ||| S:915 E:917 ||| NNP
levels ||| S:917 E:923 ||| NNS
.  ||| S:923 E:925 ||| .
During  ||| S:925 E:932 ||| IN
the  ||| S:932 E:936 ||| DT
follow-up ||| S:936 E:945 ||| JJ
,  ||| S:945 E:947 ||| ,
80  ||| S:947 E:950 ||| CD
recipients  ||| S:950 E:961 ||| NNS
presented  ||| S:961 E:971 ||| VBN
at  ||| S:971 E:974 ||| IN
least  ||| S:974 E:980 ||| JJS
one  ||| S:980 E:984 ||| CD
cardiovascular  ||| S:984 E:999 ||| JJ
event ||| S:999 E:1004 ||| NN
.  ||| S:1004 E:1006 ||| .
The  ||| S:1006 E:1010 ||| DT
total  ||| S:1010 E:1016 ||| JJ
cardiovascular  ||| S:1016 E:1031 ||| JJ
diseases  ||| S:1031 E:1040 ||| NNS
included ||| S:1040 E:1048 ||| VBD
:  ||| S:1048 E:1050 ||| :
27  ||| S:1050 E:1053 ||| CD
patients  ||| S:1053 E:1062 ||| NNS
with  ||| S:1062 E:1067 ||| IN
coronary  ||| S:1067 E:1076 ||| JJ
diseases ||| S:1076 E:1084 ||| NNS
,  ||| S:1084 E:1086 ||| ,
25  ||| S:1086 E:1089 ||| CD
with  ||| S:1089 E:1094 ||| IN
cardiac  ||| S:1094 E:1102 ||| JJ
failure ||| S:1102 E:1109 ||| NN
,  ||| S:1109 E:1111 ||| ,
18  ||| S:1111 E:1114 ||| CD
with  ||| S:1114 E:1119 ||| IN
arrhythmia ||| S:1119 E:1129 ||| NN
,  ||| S:1129 E:1131 ||| ,
11  ||| S:1131 E:1134 ||| CD
with  ||| S:1134 E:1139 ||| IN
acute  ||| S:1139 E:1145 ||| JJ
cerebrovascular  ||| S:1145 E:1161 ||| JJ
events  ||| S:1161 E:1168 ||| NNS
and  ||| S:1168 E:1172 ||| CC
19  ||| S:1172 E:1175 ||| CD
with  ||| S:1175 E:1180 ||| IN
peripheral  ||| S:1180 E:1191 ||| JJ
vascular  ||| S:1191 E:1200 ||| JJ
disease ||| S:1200 E:1207 ||| NN
.  ||| S:1207 E:1209 ||| .
Cardiovascular  ||| S:1209 E:1224 ||| JJ
events  ||| S:1224 E:1231 ||| NNS
were  ||| S:1231 E:1236 ||| VBD
not  ||| S:1236 E:1240 ||| RB
associated  ||| S:1240 E:1251 ||| VBN
with  ||| S:1251 E:1256 ||| IN
25 ||| S:1256 E:1258 ||| CD
( ||| S:1258 E:1259 ||| -LRB-
OH ||| S:1259 E:1261 ||| NNP
) ||| S:1261 E:1262 ||| -RRB-
D  ||| S:1262 E:1264 ||| NNP
levels  ||| S:1264 E:1271 ||| NNS
or  ||| S:1271 E:1274 ||| CC
vitamin  ||| S:1274 E:1282 ||| JJ
D  ||| S:1282 E:1284 ||| NNP
status ||| S:1284 E:1290 ||| NN
,  ||| S:1290 E:1292 ||| ,
and  ||| S:1292 E:1296 ||| CC
the  ||| S:1296 E:1300 ||| DT
10-year  ||| S:1300 E:1308 ||| JJ
cumulative  ||| S:1308 E:1319 ||| JJ
incidence  ||| S:1319 E:1329 ||| NN
was  ||| S:1329 E:1333 ||| VBD
29.3 ||| S:1333 E:1337 ||| CD
%  ||| S:1337 E:1339 ||| NN
for  ||| S:1339 E:1343 ||| IN
normal  ||| S:1343 E:1350 ||| JJ
vitamin  ||| S:1350 E:1358 ||| JJ
D  ||| S:1358 E:1360 ||| NNP
status  ||| S:1360 E:1367 ||| NN
and  ||| S:1367 E:1371 ||| CC
31.6 ||| S:1371 E:1375 ||| CD
%  ||| S:1375 E:1377 ||| NN
for  ||| S:1377 E:1381 ||| IN
insufficiency  ||| S:1381 E:1395 ||| NN
and  ||| S:1395 E:1399 ||| CC
51.9 ||| S:1399 E:1403 ||| CD
%  ||| S:1403 E:1405 ||| NN
for  ||| S:1405 E:1409 ||| IN
deficiency  ||| S:1409 E:1420 ||| NN
( ||| S:1420 E:1421 ||| -LRB-
P  ||| S:1421 E:1423 ||| NN
=  ||| S:1423 E:1425 ||| SYM
0.216 ||| S:1425 E:1430 ||| CD
) ||| S:1430 E:1431 ||| -RRB-
.  ||| S:1431 E:1433 ||| .
Furthermore ||| S:1433 E:1444 ||| RB
,  ||| S:1444 E:1446 ||| ,
Cox  ||| S:1446 E:1450 ||| NNP
univariate  ||| S:1450 E:1461 ||| JJ
analysis  ||| S:1461 E:1470 ||| NN
showed  ||| S:1470 E:1477 ||| VBD
no  ||| S:1477 E:1480 ||| DT
association  ||| S:1480 E:1492 ||| NN
between  ||| S:1492 E:1500 ||| IN
cardiovascular  ||| S:1500 E:1515 ||| JJ
events  ||| S:1515 E:1522 ||| NNS
and  ||| S:1522 E:1526 ||| CC
vitamin  ||| S:1526 E:1534 ||| JJ
D  ||| S:1534 E:1536 ||| NNP
levels  ||| S:1536 E:1543 ||| NNS
or  ||| S:1543 E:1546 ||| CC
vitamin  ||| S:1546 E:1554 ||| JJ
D  ||| S:1554 E:1556 ||| NNP
status ||| S:1556 E:1562 ||| NN
.  ||| S:1562 E:1564 ||| .
In  ||| S:1564 E:1567 ||| IN
addition ||| S:1567 E:1575 ||| NN
,  ||| S:1575 E:1577 ||| ,
53  ||| S:1577 E:1580 ||| CD
recipients  ||| S:1580 E:1591 ||| NNS
presented  ||| S:1591 E:1601 ||| VBN
at  ||| S:1601 E:1604 ||| IN
least  ||| S:1604 E:1610 ||| JJS
one  ||| S:1610 E:1614 ||| CD
malignancy ||| S:1614 E:1624 ||| NN
:  ||| S:1624 E:1626 ||| :
33  ||| S:1626 E:1629 ||| CD
non-melanoma  ||| S:1629 E:1642 ||| JJ
skin  ||| S:1642 E:1647 ||| NN
malignancies  ||| S:1647 E:1660 ||| NNS
and  ||| S:1660 E:1664 ||| CC
20  ||| S:1664 E:1667 ||| CD
non-skin  ||| S:1667 E:1676 ||| JJ
malignancies  ||| S:1676 E:1689 ||| NNS
( ||| S:1689 E:1690 ||| -LRB-
5  ||| S:1690 E:1692 ||| CD
prostate ||| S:1692 E:1700 ||| NN
,  ||| S:1700 E:1702 ||| ,
3  ||| S:1702 E:1704 ||| CD
kidney  ||| S:1704 E:1711 ||| NN
and  ||| S:1711 E:1715 ||| CC
urinary  ||| S:1715 E:1723 ||| JJ
tract ||| S:1723 E:1728 ||| NN
,  ||| S:1728 E:1730 ||| ,
2  ||| S:1730 E:1732 ||| CD
colon ||| S:1732 E:1737 ||| NN
,  ||| S:1737 E:1739 ||| ,
2  ||| S:1739 E:1741 ||| CD
lung ||| S:1741 E:1745 ||| NN
,  ||| S:1745 E:1747 ||| ,
2  ||| S:1747 E:1749 ||| CD
lymphoma ||| S:1749 E:1757 ||| NN
,  ||| S:1757 E:1759 ||| ,
2  ||| S:1759 E:1761 ||| CD
breast  ||| S:1761 E:1768 ||| NN
and  ||| S:1768 E:1772 ||| CC
4  ||| S:1772 E:1774 ||| CD
from  ||| S:1774 E:1779 ||| IN
other  ||| S:1779 E:1785 ||| JJ
locations ||| S:1785 E:1794 ||| NNS
) ||| S:1794 E:1795 ||| -RRB-
.  ||| S:1795 E:1797 ||| .
The  ||| S:1797 E:1801 ||| DT
cumulative  ||| S:1801 E:1812 ||| JJ
incidence  ||| S:1812 E:1822 ||| NN
of  ||| S:1822 E:1825 ||| IN
malignancies  ||| S:1825 E:1838 ||| NN
was  ||| S:1838 E:1842 ||| VBD
21.3 ||| S:1842 E:1846 ||| CD
%  ||| S:1846 E:1848 ||| NN
for  ||| S:1848 E:1852 ||| IN
normal  ||| S:1852 E:1859 ||| JJ
vitamin  ||| S:1859 E:1867 ||| JJ
D  ||| S:1867 E:1869 ||| NNP
status ||| S:1869 E:1875 ||| NN
,  ||| S:1875 E:1877 ||| ,
22.7 ||| S:1877 E:1881 ||| CD
%  ||| S:1881 E:1883 ||| NN
for  ||| S:1883 E:1887 ||| IN
insufficiency  ||| S:1887 E:1901 ||| NN
and  ||| S:1901 E:1905 ||| CC
16.7 ||| S:1905 E:1909 ||| CD
%  ||| S:1909 E:1911 ||| NN
for  ||| S:1911 E:1915 ||| IN
deficiency  ||| S:1915 E:1926 ||| NN
( ||| S:1926 E:1927 ||| -LRB-
P  ||| S:1927 E:1929 ||| NN
=  ||| S:1929 E:1931 ||| SYM
0.818 ||| S:1931 E:1936 ||| CD
) ||| S:1936 E:1937 ||| -RRB-
.  ||| S:1937 E:1939 ||| .
Our  ||| S:1939 E:1943 ||| PRP$
data  ||| S:1943 E:1948 ||| NNS
suggested  ||| S:1948 E:1958 ||| VBD
that  ||| S:1958 E:1963 ||| DT
low  ||| S:1963 E:1967 ||| JJ
vitamin  ||| S:1967 E:1975 ||| JJ
D  ||| S:1975 E:1977 ||| NNP
levels  ||| S:1977 E:1984 ||| NNS
were  ||| S:1984 E:1989 ||| VBD
not  ||| S:1989 E:1993 ||| RB
associated  ||| S:1993 E:2004 ||| VBN
with  ||| S:2004 E:2009 ||| IN
an  ||| S:2009 E:2012 ||| DT
increased  ||| S:2012 E:2022 ||| JJ
risk  ||| S:2022 E:2027 ||| NN
of  ||| S:2027 E:2030 ||| IN
cardiovascular  ||| S:2030 E:2045 ||| JJ
diseases  ||| S:2045 E:2054 ||| NNS
or  ||| S:2054 E:2057 ||| CC
malignancies ||| S:2057 E:2069 ||| NN
.  ||| S:2069 E:2071 ||| .
However ||| S:2071 E:2078 ||| RB
,  ||| S:2078 E:2080 ||| ,
due  ||| S:2080 E:2084 ||| JJ
to  ||| S:2084 E:2087 ||| TO
the  ||| S:2087 E:2091 ||| DT
small  ||| S:2091 E:2097 ||| JJ
number  ||| S:2097 E:2104 ||| NN
of  ||| S:2104 E:2107 ||| IN
patients  ||| S:2107 E:2116 ||| NNS
and  ||| S:2116 E:2120 ||| CC
events ||| S:2120 E:2126 ||| NNS
,  ||| S:2126 E:2128 ||| ,
the  ||| S:2128 E:2132 ||| DT
results  ||| S:2132 E:2140 ||| NNS
should  ||| S:2140 E:2147 ||| MD
not  ||| S:2147 E:2151 ||| RB
be  ||| S:2151 E:2154 ||| VB
considered  ||| S:2154 E:2165 ||| VBN
as  ||| S:2165 E:2168 ||| IN
definitive ||| S:2168 E:2178 ||| JJ
.  ||| S:2178 E:2180 ||| .
Additional  ||| S:2180 E:2191 ||| JJ
studies  ||| S:2191 E:2199 ||| NNS
with  ||| S:2199 E:2204 ||| IN
a  ||| S:2204 E:2206 ||| DT
higher  ||| S:2206 E:2213 ||| JJR
number  ||| S:2213 E:2220 ||| NN
of  ||| S:2220 E:2223 ||| IN
patients  ||| S:2223 E:2232 ||| NNS
are  ||| S:2232 E:2236 ||| VBP
required  ||| S:2236 E:2245 ||| VBN
to  ||| S:2245 E:2248 ||| TO
elucidate  ||| S:2248 E:2258 ||| VB
the  ||| S:2258 E:2262 ||| DT
true  ||| S:2262 E:2267 ||| JJ
impact  ||| S:2267 E:2274 ||| NN
of  ||| S:2274 E:2277 ||| IN
vitamin  ||| S:2277 E:2285 ||| JJ
D  ||| S:2285 E:2287 ||| NNP
status  ||| S:2287 E:2294 ||| NN
on  ||| S:2294 E:2297 ||| IN
cardiovascular  ||| S:2297 E:2312 ||| JJ
and  ||| S:2312 E:2316 ||| CC
malignancy  ||| S:2316 E:2327 ||| JJ
risks ||| S:2327 E:2332 ||| NNS
.  ||| S:2332 E:2334 ||| .
